AMPK emerges as a key mediator in the dysregulation and highlights its potential as a therapeutic target to mitigate the adverse effects of obesity on mitochondrial biogenesis and mtDNA heteroplasmy, oocyte maturation and quality, offering promising avenues to improve reproductive and health outcomes of both mothers and their offspring. Here, PRKAA1 is linked to obesity disorder.